Antimicrobial activity of ceftolozane-tazobactam against multidrug-resistant and extensively ddrug-resistant pseudomonas aeruginosa clinical isolates from a spanish Hospital

López-Calleja, Ana Isabel ; Morilla, Elena ; Nuñez, Rossi ; Fernández Esgueva, Marta ; Sahagún, Juan (Universidad de Zaragoza) ; García-Lechuz, Juan Manuel ; Ferrer Cerón, Isabel ; Viñuelas, Jesús (Universidad de Zaragoza) ; Rezusta, Antonio (Universidad de Zaragoza)

Resumen: Objectives. Our objective was to evaluate the in vitro activity of ceftolozane-tazobactam against multidrugresistant (MDR) and extensively drug-resistant (XDR) non metallo-β-lactamase producing Pseudomonas aeruginosa clinical isolates at Hospital Universitario Miguel Servet (Zaragoza, Spain) from February 2016 to October 2017. Material and methods. We evaluated the in vitro activity of ceftolozane-tazobactam and other antipseudomonal antibiotics against 12 MDR and 117 XDR non metallo-β-lactamase producing P. aeruginosa isolates. Ceftolozane-tazobactam minimal inhibitory concentrations (MICs) were determined by MIC gradient diffusion test strip. Results. Among the 129 MDR/XDR isolates included, 119 (92.2%) were susceptible to ceftolozane-tazobactam, and ten (7.8%) were resistant. MIC50 was 2 mg/L, and MIC90 4 mg/L. Ceftolozane-tazobactam was the second most active antibiotic after colistin, overtaking amikacin. Conclusions. Ceftolozane-tazobactam is a valuable treatment option for MDR and XDR P. aeruginosa infections in our setting.

Idioma: Inglés

Año: 2019

Publicado en: Revista española de quimioterapia 32, 1 (2019), 68-72
ISSN: 0214-3429

Factor impacto JCR: 1.132 (2019)

Categ. JCR: PHARMACOLOGY & PHARMACY rank: 246 / 270 = 0.911 (2019) - Q4 - T3
Categ. JCR: MICROBIOLOGY rank: 121 / 133 = 0.91 (2019) - Q4 - T3

Factor impacto SCIMAGO: 0.287 - Medicine (miscellaneous) (Q3) - Pharmacology (Q3) - Microbiology (medical) (Q3)

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Área Microbiología (Dpto. Microb.Med.Pr.,Sal.Públ.)